Current strategies for the prevention of influenza by the Russian cold-adapted live influenza vaccine among different populations

Abstract

Trivalent live attenuated influenza vaccine (LIV) prepared from the donor strains A/Len/134/17/57 (H2N2) and B/USSR/60/69 demonstrated safety, immunogenicity, genetic stability for a single dose in children from 3 years old. The vaccine efficacy against serologically and virologically confirmed influenza virus infection was 94.4% for children 7–14 years old and 92.9% for children 3–6 years old. An improved strategy for immunizing the elderly with a combination of LIV and inactivated vaccine has been developed. This strategy has been estimated to be 68% effective against influenza. The proposed strategy uses LIV based on the donor strains A/Len/134/17/57 (H2N2) and B/USSR/60/69 for different population groups. The LIV may also have a potential use in the event of an influenza pandemic.